• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IBX 3.13% 3.3¢


We are a multidisciplinary team with expertise in the physics of magnetic fields and... We are a multidisciplinary team with expertise in the physics of magnetic fields and nanotechnology & the medical application of these fields. By combining high sensitivity imaging technologies with nanoparticle technology, we aim to make the detection of diseases like cancer better and safer for patients as well as provide new methods for therapeutic intervention.More

Recently Updated

Corporate Spotlight

We are a multidisciplinary team with expertise in the physics of magnetic fields and nanotechnology & the medical application of these fields. By combining high sensitivity imaging technologies with nanoparticle technology, we aim to make the detection of diseases like cancer better and safer.
View the full Corporate Spotlight arrow Created with Sketch.

Investor Updates with Robert Proulx, CEO IBX July


arrow-down-2 Created with Sketch.

Investor Update with Imagion Biosystems CEO, Robert Proulx - Discussing upcoming Australian Human Studies and MagSense Technology - July 2020

First in-human study update – Webcast Presentation - 23rd June 2020

Investor Updates with Imagion Biosystems CEO, Robert Proulx - May 2020

The Market Herald Bulletin: Imagion Biosystems (ASX:IBX) director resigns, to raise over $2M - 26th March 2020

The Market Herald: Investment Opportunity in Medical Imaging - Special Report March

Video Interview with Robert Proulx, CEO Imagion Biosystems - March


arrow-down-2 Created with Sketch.

Imagion announces plan to undertake first clinical study in Australia Live Webcast Scheduled

ASX Release 22nd June 2020

Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce its plans to conduct its first-in-human study in Australia. The study will be the first time the MagSenseTM diagnostic imaging technology will be used in a clinical setting. Additionally, the Company intends to expand the study to investigate the utility of its nanoparticles as a Magnetic Resonance Imaging (MRI) contrast agent.

The Phase I study aims to evaluate the Company’s MagSenseTM HER2 nanoparticle test reagent for safety and initial effectiveness for lymph nodal metastases in HER2 breast cancer. The multi-site study is expected to enroll 15 to 20 patients, beginning in the fourth quarter of 2020, subject to Human Research Ethics Committee (HREC) approval and having study sites under contract.

“It is well known that there is a favorable regulatory and clinical testing environment for Phase I studies in Australia. For Imagion, there are a number of advantages to conducting the study in Australia, including a lower overall cost and the ability to expand the study to include MRI and still execute within our desired timeframes, thanks to the recently announced collaboration with Siemens Healthineers,” said Bob Proulx, Executive Chairman of Imagion Biosystems.

“While the primary objective of the study is to demonstrate that our nanoparticles are safe, it will also generate valuable data to show the effectiveness of our targeted nanoparticles in detecting the presence and spread of HER2 breast cancer using two different imaging modes. These study data will help us assess the best commercial pathway for improving nodal staging of HER2 breast cancer.

“We have worked hard to hold to our goal of entering the clinic this year. As previously reported, the first phase of manufacturing has been completed on time and the second phase continues on schedule, with no impact from the global pandemic so far. We are now focused on securing the clinical sites and obtaining the necessary clearances to commence the study.”

Imagion’s proprietary MagSenseTM technology works by using tiny bio-safe nanoparticles coated with tumour targeting antibodies to tag the cancer. MagSenseTM sensors are able to detect the particles which have become attached to cancer cells and which then act like a magnetic beacon. This imaging method, known as super magnetic relaxometry (SMPR), has been designated by the FDA as a Breakthrough Device for its potential to change cancer staging and diagnoses.

In the MRI setting, contrast agents are used to enhance the image and improve resolution but are typically general contrast agents and do not provide specific bio-functional information. Imagion’s MagSenseTM nanoparticles could provide an enhanced MR image of specific diseased tissue, thus improving on the ability to identify cancer tissues with existing imaging technology.

In May 2020, Imagion Biosystems entered into a collaboration agreement with Siemens Healthcare Pty Ltd of Australia (Siemens Healthineers) to further explore the utility of Imagion’s MagSenseTM nanoparticles as an MRI contrast agent.

Investor Webcast

Imagion Biosystems President and CEO Bob Proulx will host a webcast and Q&A with investors on Tuesday 23 June 2020 at 10:30am AEST.

Investors are invited to register for the webcast at the following link:https://zoom.us/webinar/register/WN_a5FHdeI1QbuZPKDkT_bc2g

Registered participants will receive a confirmation email containing the Zoom access link and alternative phone dial-in details.

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

ASX Release 22nd June 2020


arrow-down-2 Created with Sketch.

Imagion Biosystems establishes collaboration with Siemens Healthineers

ASX Announcement 20 May 2020 

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, announces it has entered into a collaboration agreement with Siemens Healthcare Pty Ltd of Australia (Siemens Healthineers) to further explore the utility of Imagion’s MagSense™ nanoparticles as an MRI contrast agent.

The collaboration will see Siemens Healthineers work with Imagion to identify optimal MRI scanning protocols for the MagSense™ HER2 targeted nanoparticles. Siemens Healthineers in-kind contribution of expertise and provision of technical support to clinical sites will be valuable should Imagion undertake a study in Australia which includes MRI scans.

Imagion has previously announced that it is planning for its first clinical study of the MagSense™ technology in HER2 breast cancer patients. The MagSense™ nanoparticles are designed to be detectable only when attached to cancer cells providing a specific means of cancer imaging, and has a received Breakthrough Device designation from the US Food and Drug Administration (FDA). The collaboration with Siemens is in line with Imagion’s strategy to explore an additional and alternative use of the MagSense™ nanoparticles as an MRI contrast agent. 

Imagion Biosystems presented its first data showing that the MagSense™ nanoparticles could be used as a magnetic resonance imaging agent, at the World Molecular Imaging Conference in September 2019. This collaboration establishes a path for Imagion to further explore MRI as a commercial pathway leveraging the large global installed base of existing MRI scanners.

Contrast agents are used to enhance the image and improve resolution. To-date, imaging agents have been general purpose, creating contrast at tissue boundaries but not providing functional imaging utility. A targeted MagSense™ nanoparticle could be used as a contrast agent to enhance an MR image of specific diseased tissue, thus providing a clear and accurate method to use imaging to non-invasively detect cancer with existing imaging technology.

“We are very pleased to have Siemens Healthineers offer of assistance as we look at all the possibilities to develop and commercialize our technology,” said Bob Proulx, Executive Chairman of Imagion Biosystems. “The ability to use a targeted contrast agent like ours, in the MRI setting, could transform the way MRI is used to diagnose cancer and other diseases. In entering into this collaboration, we will jointly gain insight into the clinical and commercial potential of our novel technology. We are proud that Imagion continues to attract the support of leading industry players and opinion leaders.” 

“Siemens Healthineers has a strong focus on expanding Precision Medicine and transforming care delivery,” said Dr Kieran O’Brien, Head of Collaborations and Research for Australia and New Zealand for Siemens Healthcare Pty Ltd, “Imagion’s targeted contrast technology MagSense™ could offer patients a more specific means to monitor cancer with MRI, and we look forward to assisting Imagion in investigating the application of their technology with MRI scanners.”

Siemens Healthineers is a leading medical technology company. With over 120 years of experience, Siemens Healthineers is enabling healthcare providers to increase their value through digitalised healthcare. Siemens Healthineers portfolio of products and services is largely compromised of its core areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine.

Click here to view the full announcement


arrow-down-2 Created with Sketch.


ASX Release 19th May 2020

Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to share news of a recent publication, led by researchers at the Weill Cornell Medical College, which reports use of the company’s nanoparticles in investigating a human immunodeficiency virus type -1 (HIV-1) therapy.

The work, published in the Journal of Virology (March 2020 Volume 94 Issue 6) illustrates how iron oxide nanoparticles could be used in conjunction with viral specific agents to create “a particulate immunogen” that stimulates the body’s immune response through neutralizing antibody (NAb) induction. The publication can be download here https://t.co/CaV8FWfuhX?amp=1.

“We are very happy to see new biomedical applications being developed from the commercial sale of our PrecisionMRX® brand of nanoparticles,” said Bob Proulx, Executive Chairman of Imagion Biosystems. “The COVID-19 pandemic has raised everyone’s awareness of the need to develop better therapies and vaccines for viral diseases. Nanoparticles may provide an important role in the development of effective treatments. While we remain focused on our goal of developing the nanoparticles for the detection of cancer through our MagSenseTM programs, it is clear there are many potential clinical applications in which our nanoparticles can be applied, and we are keen to identify prospective partners in these areas. Our investment in manufacturability of our nanoparticles puts us in a good position to be a prospective partner or supplier if research leads to commercial applications.”

Read the full ASX Release Here


arrow-down-2 Created with Sketch.

Read The Article on The Market Herald Here

Medical imaging is revolutionising the way we think about health. Ever-evolving technology continues to agitate key players in the space, pushing them to deliver new tests that detect problems faster and more accurately than ever before.

But if this is such a crucial field, why haven't we heard more about it?

Currently, there's pain in the pricing. Medical imaging equipment can be expensive for hospitals to install and maintain. Moreover, radiology exams may not be covered by health insurance policies or subsidised by the government — leaving patients out of pocket or unable to afford crucial testing.

On top of that, current imaging technology isn't always diagnostic; it may not be able to tell if a cancer is malignant or benign and is often invasive, or even painful.

So as healthcare expenditure continues to rise, radiologists face a challenge. They'll need to work with technology to create cost-effective, efficient and less invasive medical imaging strategies.

In doing so, companies can ensure life-saving testing is more widely accessible. But even more importantly, the growing efficacy of imaging technology will change the way we detect and treat diseases like cancer and arthritis.

Consequently, there's great value to be had in the medical imaging space — and some of our ASX-listed biotechs are more than ready to shake up the field.

An Emerging Technology

Over the last few decades, there's been something of a space race in the medical imaging industry. Companies compete to be the best and brightest in radiology, trying to develop the fastest machine with the highest imaging technology. But nowadays, the bar is even higher.

Karim Boussebaa, senior vice president of Computed Tomography (CT) and Advanced Molecular Imaging (AMI) for Philips, says there's an emphasis on uncovering advanced imaging strategies.

"Not only are we interested in diagnosing the right disease in our patient but it's also important that we do it in the most effective and the most efficient way," Karim explained.

Experts say another catalyst to this competition is rising healthcare costs. In the U.S. alone, health-related expenditure accounted for between six and 15 per cent of the Gross National Product (GNP) in 2012. Moreover, between three and five per cent of this was spent on medical imaging.

"As people are looking to purchase new pieces of equipment it is no longer just about the latest and greatest, but it is going to be more focused," said Samir Patel, a program director to Radiology, Inc.

The market for medical imaging has also expanded in the last half-century – where there used to be three of four big names in the field, there are now many more looking for a slice in the pie. As a result, fresh faces have brought new standards and are pushing companies to innovate like never before.

The Key Imaging Players

Fortunately, many homegrown biotech companies are actively exploring the medical imaging space. 

In fact, there are seven ASX-listed players working in the imaging technology field, such as Imagion Biosystems (ASX:IBX), Resonance Health (ASX:RHT) and Compumedics (ASX:CMP). Meanwhile, names like Uscom (ASX:UCM) and Impedimed (ASX:IPD) are developing monitoring and medical devices.

While each of these companies have different targets, they all have some involvement in administering or developing technology to carry out diagnostic imaging, ultrasounds, CT or PET scans and radiology services.


(20min delay)
Mkt cap ! $25.13M
Open High Low Value Volume
3.4¢ 3.5¢ 3.3¢ $166.3K 4.902M

Buyers (Bids)

No. Vol. Price($)
4 433793 3.3¢

Sellers (Offers)

Price($) Vol. No.
3.4¢ 132421 2
View Market Depth
Last trade - 16.10pm 03/07/2020 (20 minute delay) ?
0.001 ( 3.34 %)
Open High Low Volume
3.4¢ 3.5¢ 3.3¢ 1662823
Last updated 15.47pm 03/07/2020 (live) ?
IBX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.